OPTICAL CHERENKOV IMAGING DOSIMETRY IN HUMAN RADIOTHERAPY
Project Number5R01EB023909-08
Former Number2R01EB023909-05
Contact PI/Project LeaderPOGUE, BRIAN W. Other PIs
Awardee OrganizationUNIVERSITY OF WISCONSIN-MADISON
Description
Abstract Text
ABSTRACT
Optical imaging of Cherenkov emission from tissue during radiotherapy has been demonstrated in humans,
providing a map correlated to radiation dose within the surface tissues. In external beam radiotherapy, the signal
is optimally captured by time-gated intensified cameras, synchronized to the linear accelerator pulses, allowing
rejection of the majority of background room light, and providing real time video of each radiotherapy treatment
with standard dose rates. This discovery combined with CT and reflectance calibration has the potential to allow
accurate quantitative dose imaging in humans for the first time in the history of therapeutic radiation use. While
the imaging technology has inherent limitations to surface regions, the fact that it is a real time imaging tool and
provide visual recording of every feature of a treatment plan is revolutionary. It has the potential for a paradigm
change in how radiotherapy is documented and archived for daily reliance, quality audit and potentially
automated control of delivery. The implementation of Cherenkov imaging is significantly simpler than most
dosimetry tools, however the understanding and interpretation of the images need to be established, in order to
be clear about what is possible in imaging delivery of dose. This proposed technology developments advance
the methods for quantitative dose imaging in whole breast radiation treatment using our patented approach to
CT/reflectance calibration of Cherenkov imaging, will be advanced and tested in regular treatments. Additionally,
we will advance the ability to image patients with complex multi-field treatments, where adjacent beam fields are
matched, so that we can quantify the dose accuracy at the match lines. Another application is treatment of total
skin with electron therapy, where the field is extremely large and so imaging dosimetry makes sense. Our
preliminary data indicates that areas of chronic underexposure exist today and the optimal delivery technique
will be defined by our efforts in imaging and 3D animation & visualization of total body skin dose, developing an
optimized imaging system to identify the ideal treatment technique for patients of different body shape. Finally,
Cherenkov imaging is synergistic with scintillator imaging of dose, and this will be advanced as a related tool to
remotely quantify skin dose. Taken together, this project will advance the only way to directly image radiotherapy
dose and delivery on the patient’s tissue. The core of the project is combined technology systems, leveraging a
large installed base of cameras and national partnerships advancing this field. This technology is embryonic but
on the cusp of commercialization, where the focus of this research project being to advance the science and
methods of where it can add value to radiotherapy. The long term benefit of advancing this technology will be to
change the way in which radiotherapy incidents are observed by the therapist team and have these recorded on
a daily basis in every treatment center.
Public Health Relevance Statement
NARRATIVE
Cherenkov imaging of radiation therapy delivery allows a real time visual mapping of the surface
radiation deposited by the beam in the patients tissue. Developments to use this signal
quantitatively as a dose imaging tool are developed in this work, for applications in external beam
radiotherapy.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
161202122
UEI
LCLSJAGTNZQ7
Project Start Date
01-March-2022
Project End Date
31-January-2026
Budget Start Date
01-February-2024
Budget End Date
31-January-2026
Project Funding Information for 2024
Total Funding
$578,087
Direct Costs
$513,700
Indirect Costs
$64,387
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$578,087
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB023909-08
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB023909-08
Patents
No Patents information available for 5R01EB023909-08
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB023909-08
Clinical Studies
No Clinical Studies information available for 5R01EB023909-08
News and More
Related News Releases
No news release information available for 5R01EB023909-08
History
No Historical information available for 5R01EB023909-08
Similar Projects
No Similar Projects information available for 5R01EB023909-08